Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for
compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s),
including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have
incomplete response to or have exhausted available therapies.